Metyrosine Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 250 mg
Reference Brands: Demser (USA/EU)
Category:
Neurology
Metyrosine is available in Capsules
and strengths such as 250 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Metyrosine is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Metyrosine can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Metyrosine is a methylated tyrosine derivative that acts as a catecholamine synthesis antagonist with antihypertensive properties. It functions by selectively and competitively inhibiting the enzyme tyrosine 3-monooxygenase (tyrosine hydroxylase), which catalyzes the conversion of tyrosine to dihydroxyphenylalanine (DOPA), a key intermediate in the production of catecholamines, including dopamine, norepinephrine, and epinephrine.
By reducing catecholamine synthesis, metyrosine helps manage the elevated hormone levels commonly seen in patients with pheochromocytoma, a rare tumor of the adrenal glands. This decrease in catecholamines contributes to improved control of hypertension and associated cardiovascular symptoms.
Metyrosine is administered orally in capsule form and is primarily used as a preoperative adjunct to stabilize patients before surgical removal of pheochromocytoma. It is also employed in patients with inoperable or malignant tumors to help manage excessive catecholamine-mediated symptoms. By targeting the root cause of catecholamine overproduction, metyrosine provides a pharmacologic option for symptom control in this endocrine disorder.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing